Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NASDAQ | Common Stock
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer.
The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.
The company is headquartered in Boulder, Colorado.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 24 | -0.41 Increased by 0.00% | -0.55 Increased by +25.45% |
| May 14, 24 | -0.54 Increased by +32.50% | -0.57 Increased by +5.26% |
| Mar 14, 24 | -0.47 Decreased by -138.84% | -0.54 Increased by +12.96% |
| Nov 9, 23 | -0.51 Increased by +29.17% | -0.47 Decreased by -8.51% |
| Aug 10, 23 | -0.41 Increased by +76.70% | -0.36 Decreased by -13.89% |
| May 11, 23 | -0.80 Increased by +64.29% | -0.63 Decreased by -26.98% |
| Feb 10, 23 | 1.21 Increased by +157.08% | -0.79 Increased by +253.94% |
| Oct 25, 22 | -0.72 Increased by +67.27% | -1.00 Increased by +28.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | N/A Decreased by N/A% | -23.16 M Decreased by -11.49% | - - |
| Jun 30, 24 | 0.00 Decreased by N/A% | -19.95 M Decreased by -19.31% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -22.74 M Decreased by -74.50% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 440.00 K Increased by +N/A% | -19.37 M Decreased by -160.18% | Decreased by -4.40 K% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -20.77 M Decreased by -96.79% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -16.72 M Decreased by -88.11% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -13.03 M Decreased by -50.31% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | 32.19 M Increased by +483.52% | Increased by +N/A% Decreased by N/A% |